Pharmacokinetics of nAdroparin in venous thromboembolism Prophylaxis in critically ill pAtients - an observational pilot study
Completed
- Conditions
- deep venous thrombosisVenous thromboembolism10064477
- Registration Number
- NL-OMON38854
- Lead Sponsor
- Meander Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
* The patient is at least 18 years of age.
* The patient is admitted to the intensive care unit.
* The patient is already treated with nadroparin for VTE prophylaxis, or, is eligible for treatment with nadroparin for such reasons.
* The patient already has a catheter to obtain the necessary blood samples.
Exclusion Criteria
* Acute and life-threatening complications that require immediate patient treatment, as decided by the intensive care physician.
* The patient is admitted to the ICU for routine post-operative intensive care monitoring
* The patient is treated with a therapeutic dose of nadroparin
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Quantitative description of nadroparin pharmacokinetics in critically ill<br /><br>patients: changes in anti-Xa-time profiles and their possible relationship with<br /><br>critical illness</p><br>
- Secondary Outcome Measures
Name Time Method <p>Niet van toepassing</p><br>